文献速递胸部肿瘤放疗

局部晚期肺癌三维适形与调强放疗的剂量学及毒性比较:全州质量协作研究

Dosimetry and Toxicity Comparison of Three-Dimensional Conformal Radiation Therapy and Intensity Modulated Radiation Therapy in Locally Advanced Lung Cancer Across a Large Statewide Quality Collaborative.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-03-10

在MROQC前瞻性多中心州级协作中,2012至2022年共1746例接受根治性放疗(90%为放化疗)的局部晚期非小细胞肺癌患者纳入分析,其中3D-CRT组313例、IMRT组1433例。经逆概率治疗加权调整后,IMRT较3D-CRT降低了肺高剂量(平均V30 Gy 17.9% vs 19.2%;P=0.027)和心脏高剂量(V40 Gy≥20%比例6.4% vs 15.3%;P<.0001);6个月早期随访内,两组≥2级急性食管炎和≥2级早期肺炎发生率及患者报告结局的临床显著下降均无显著差异。

要点

  • IMRT组患者PTV更大(中位386 cc vs 292 cc;P<.0001),IIIB期比例更高(34.3% vs 23.0%;P<.0001)。
  • 经IPTW调整后,IMRT较3D-CRT降低肺平均V30 Gy(17.9% vs 19.2%;P=0.027)。
  • 经IPTW调整后,IMRT较3D-CRT降低心脏V40 Gy≥20%比例(6.4% vs 15.3%;P<.0001)。

核心结论

  • 在晚期随访仍在进行的情况下,本研究支持对局部晚期非小细胞肺癌继续优先使用IMRT而非3D-CRT,原因是心脏和肺剂量得到改善。

研究设计与样本

  • 密歇根放射肿瘤学质量协作组(MROQC)前瞻性、多中心、全州范围研究,2012至2022年纳入1746例符合入选标准的局部晚期非小细胞肺癌患者,均接受根治性放疗(90%为放化疗)。
  • 患者接受3D-CRT(n=313)或IMRT(n=1433),采用逆概率治疗加权(IPTW)校正两组预后因素差异。
  • 治疗期间至放疗后6个月收集医生报告的毒性和患者报告结局(PROs),按治疗技术进行比较。

主要发现

  • 与3D-CRT组相比,IMRT组PTV显著更大(中位386 cc vs 292 cc;P<.0001),IIIB期疾病比例更高(34.3% vs 23.0%;P<.0001)。
  • 经IPTW调整后,IMRT组较3D-CRT组降低肺高剂量(平均V30 Gy 17.9% vs 19.2%;P=0.027)。
  • 经IPTW调整后,IMRT组较3D-CRT组降低心脏高剂量(V40 Gy≥20%的比例6.4% vs 15.3%;P<.0001)。
  • 在IPTW逻辑回归模型中,6个月早期随访内,3D-CRT组与IMRT组≥2级急性食管炎发生率无显著差异(OR=1.02;95%CI 0.73,1.42;P=0.91)。
  • 在IPTW逻辑回归模型中,6个月早期随访内,3D-CRT组与IMRT组≥2级早期肺炎发生率无显著差异(OR=1.62;95%CI 0.89,2.96;P=0.11),PROs临床显著下降的可能性也无显著差异。

临床怎么用

  • 研究结论支持对局部晚期非小细胞肺癌继续优先使用IMRT而非3D-CRT,原因是心脏和肺剂量得到改善。

局限性

  • 晚期随访仍在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Use of intensity modulated radiation therapy (IMRT) versus three-dimensional conformal external beam radiation therapy (3D-CRT) for definitive chemoradiation therapy (CRT) in locally advanced non-small cell lung cancer (LA-NSCLC) has been associated with decreased late pneumonitis, decreased high dose to the heart (itself associated with improved overall survival), and improved patient quality of life. In a statewide radiation oncology quality consortium, we sought to evaluate the impact of IMRT versus 3D-CRT treatment technique on dosimetry and toxicity. METHODS AND MATERIALS: From 2012 to 2022, 1746 LA-NSCLC patients meeting inclusion criteria underwent definitive RT (90% CRT) with either 3D-CRT (n = 313) or IMRT (n = 1433) and were enrolled in the Michigan Radiation Oncology Quality Consortium (MROQC) prospective, multicenter statewide initiative. Physician reported toxicity and patient-reported outcomes (PROs) were collected during treatment through 6 months after RT and compared by treatment technique. Inverse probability of treatment weighting (IPTW) was used to account for differences in prognostic factors between IMRT and 3D-CRT patients. RESULTS: Compared with 3D-CRT patients, IMRT patients had significantly larger PTVs (median 386 cc vs 292 cc; P < .0001) and were more likely to have Stage IIIB disease (34.3% vs 23.0%; P < .0001). After adjustment using IPTW, treatment with IMRT compared with 3D-CRT reduced high dose to the lung (mean V30 Gy 17.9% vs 19.2%; P = .027) and heart (proportion with V40 Gy ≥ 20% 6.4% vs 15.3%; P < .0001). In logistic regression models using IPTW, through 6 months of early follow-up, there were no significant differences between 3D-CRT and IMRT in rates of grade 2+ acute esophagitis (odds ratio [OR] = 1.02; 95% CI, 0.73,1.42; P = .91) and grade 2+ early pneumonitis (OR = 1.62; 95% CI, 0.89, 2.96; P = .11) or in likelihood of a clinically significant decline in PROs. CONCLUSIONS: With late follow-up ongoing, this study supports the continued preferential use of IMRT over 3D-CRT for LA-NSCLC treatment due to improvements in heart and lung doses.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Allen SG, Schonewolf CA, Schipper MJ, et al. Dosimetry and Toxicity Comparison of Three-Dimensional Conformal Radiation Therapy and Intensity Modulated Radiation Therapy in Locally Advanced Lung Cancer Across a Large Statewide Quality Collaborative. Int J Radiat Oncol Biol Phys. 2025. PMID: 40074046. doi:10.1016/j.ijrobp.2025.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。